UNESCO Hosts National Validation Meeting for Jamaica's Health and Family Life Education Study - UNESCO

Migraines are estimated to affect 10% to 29% of women during the menopause transition, when migraines often worsen and become more frequent, especially during perimenopause. This is due to unpredictable estrogen drops. A new study suggests postmenopausal women using hormone therapy will experience more frequent, longer-lasting migraines. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026. Hormone therapy has proven to be successful in managing a wide array of bothersome menopause symptoms, especially hot flashes. A challenge, however, is that fluctuations in estrogen levels may influence migraines.

Premature menopause is associated with an increased risk of several long-term health problems due to estrogen deficiency. Cardiovascular disease (CVD) is one of those health risks. However, the underlying cardiometabolic causes are unclear. A new study suggests a possible connection with insulin levels. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego, October 20-24, 2026. Premature menopause is defined as menopause that occurs before the age of 40 years. Only about 1% of women experience it. Women who experience premature menopause have a longer duration of postmenopause life and have been reported to have higher risks of several adverse health outcomes, including cardiovascular disease and osteoporosis.

Turnover related to menopause has become a critical global socioeconomic challenge, affecting female career longevity and organizational productivity. A new study suggests that, although many employers have attempted to make special accommodations in the workplace, they fail to address a woman's increased psychological burdens related to the menopause transition. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego, October 20-24, 2026. In a new study coming out of Japan, researchers looked at more than 1,600 perimenopausal and postmenopausal working women aged 45 to 60 years. They identified 13 independent variables to control for potential confounding: age, marital status, annual income, exercising habits, psychiatric history, caregiving roles, the three distinct subscales of the Menopause Rating Scale (MRS: psychological, somatic, and urogenital subscales), and treatment-necessity awareness.

Hot flashes are the most frequent symptom of perimenopause and menopause, affecting 75% to 85% of women. In recent years, there has been a spike in the number of nonhormone options for managing hot flashes. A new study suggests that transdermal nitroglycerin may be an option. Results of the study will be presented at the 2026 Annual Meeting of The Menopause Society in San Diego October 20-24, 2026. Menopausal hot flashes are not life-threatening, but frequent or severe episodes can significantly disrupt daily life. It is estimated that between 10% and 30% of women have symptoms that are severe enough to impair daily activities, work performance, and overall quality of life. Night sweats can disrupt sleep, leading to chronic fatigue, irritability, and mood changes.

News|Articles|October 20, 2026 Day 2 of the CHEST 2026 Annual Meeting, held October 18 to 21 in Phoenix, Arizona, brought sessions spanning pulmonary vascular disease, fibrotic interstitial lung disease (ILD), and pulmonary rehabilitation access. Highlights included a review of 3 recent randomized PE trials pointing toward catheter-based intervention in sicker intermediate-risk patients, a practical session on integrating echocardiography with right heart catheterization in pulmonary hypertension, a registry analysis linking short telomeres to Usual Interstitial Pneumonia (UIP) patterning rather than fibrosis burden in ILD, and a debate-based look at new Medicare coverage enabling virtual pulmonary rehabilitation delivery. Related to this article